{"groups":[{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 1 contains patients treated at Dose Level 0 (1 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^4 - 2.80 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"FG000","title":"Dose Level 0 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 2 contains patients treated at Dose Level 1 (3.3 x 10\\^5 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^5 - 8.50 x 10\\^5 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"FG001","title":"Dose Level 1 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 3 contains patients treated at Dose Level 2 (1 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 8.51 x 10\\^5 - 2.80 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"FG002","title":"Dose Level 2 of CD20 CAR T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 4 contains patients treated at Dose Level 3 (3.3 x 10\\^6 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: 2.81 x 10\\^6 - 8.50 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"FG003","title":"Dose Level 3 of CD20 CAR-T Cells"},{"description":"Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.\n\nArm 5 contains patients treated at Dose Level 4 (1 x 10\\^7 tCD19+ T cells/kg, CAR T Cell Dose Inclusion Range: \\> 8.5 x 10\\^6 tCD19+ T cells/kg)\n\nChimeric Antigen Receptor T Cell Therapy: CD20 CAR T cell IV\n\nLeukapheresis: Undergo leukapheresis\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV","id":"FG004","title":"Dose Level 4 of CD20 CAR-T Cells"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"20"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Fifty-three participants were enrolled but three participants did not move on to treatment due to worsening of their disease status. They were not assigned to a treatment dose level."}